Dingding Kang1,*, Liushan Wei2, Lianmei Xu2, Liwei Yi1
1Affiliated Nanhua Hospital, Department of Pharmacy, Hengyang Medical School, University of South China, Hengyang 421001, Hunan, China.
2School of Pharmacy, Hengyang Medical School, University of South China, Hengyang 421001, Hunan, China.
*Corresponding author: Dingding Kang
References
[1] Goldfarb MJ, Bechtel C, Capers Q 4th, et al. Engaging Families in Adult Cardiovascular Care: A Scientific Statement from the American Heart Association. Journal of the American Heart Association. 2022;11(10):e025859.
[2] Pereira NL, Rihal C, Lennon R, et al. Effect of CYP2C19 genotype on ischemic outcomes during oralp2y 12 inhibitor therapy. JACC-Cardiovascular Interventions. 2021;14(7):739-750.
[3] Lee YC, Liao YC, LIN C J, et al. Baseline P2Y12 reactivity, kidney function, and CYP2C19 genotype determine clopidogrel responsiveness in acute stroke. Scientific Reports. 2023;13(1):8085.
[4] Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metabolism & Disposition the Biological Fate of Chemicals. 2010;38(1):92-99.
[5] Patel S, Arya V, Saraf A, et al. Aspirin and Clopidogrel Resistance in Indian Patients with Ischemic Stroke and its Associations with Gene Polymorphisms: A Pilot Study. Annals of Indian Academy of Neurology. 2019;22(2).
[6] Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. New England Journal of Medicine. 2010;363(18):1704-1714.
[7] Lima JJ, Thomas CD, Barbarino J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clinical Pharmacology & Therapeutics. 2021;109(6):1417-1423.
[8] Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clinical Pharmacology & Therapeutics. 2013;94(3):317-323.
[9] Hokimoto S, Akasaka T, Tabata N, et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. Thrombosis Research. 2015;135(6):1081-1086.
[10] The health and family planning commission of the People's Republic of China. Summary of the technical guidelines for column measurement of drug metabolism enzymes and drug action target genes (trial). Practical Organ Transplantation Electronic Journal. 2015;3(5):257-267.
[11] Huang H, Zhang S, Du H, Guo Y, Zheng H. Effect of Clopidogrel combined with aspirin in the treatment of acute progressive cerebral infarction: A retrospective single-center analysis. Pakistan Journal of Medical Sciences. 2024;40(5):891-895.
[12] Yao Y, Tang XF, Zhang JH, et al. Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention. Thrombosis Research. 2016;141:28-34.
[13] Hui Z, Lin S, Hui XL, et al. Gene polymorphism of aspirin-induced urticaria in children with Kawasaki disease. Frontiers in Pediatrics. 2019;7:505-505.
[14] Mastalerz L, Setkowicz M, Sanak M, et al. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. Journal of Allergy and Clinical Immunology. 2004;113(4):771-775.
[15] Mastalerz L, Setkowicz M, Sanak M, et al. Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. British Journal of Dermatology. 2006;154(2):256-260.